

**AMENDMENTS TO THE CLAIMS**

(7)

1-24 (Previously Cancelled)

25. (Currently Cancelled)

26. (Currently Cancelled)

27. (Currently Amended) A method of treatment of allergy and asthma patients in need of [~~multiple drugs daily~~] such treatment, comprising administering [~~the~~] a pharmaceutical composition [~~of claim 25~~] consisting essentially of glycoposphopeptical in multiple doses for a short term [~~course~~] treatment period of [~~1-14~~] 1-20 days to induce a remission of [~~3-12~~] several months during which further treatment is not necessary.

28. (Previously Withdrawn)

29. (Previously Withdrawn)

30. (Previously Withdrawn)

31. (Previously Withdrawn)

32. (Previously Withdrawn)

33. (Previously Withdrawn)

34. (Previously Withdrawn)

35. (New) The method of claim 27 wherein the short term treatment period lasts 3-5 days.

36. (New) The method of claim 27 wherein the glycoposphopeptical is administered in doses up to 2000mg.

37. (New) The method of claim 36 wherein the glycoposphopeptical is administered in doses of 200-1000mg.

38. (New) The method of claim 27 wherein the glycoposphopeptical is administered in doses at least once daily up to 10 times daily.

39. (New) The method of claim 27 wherein the glycoposphopeptical is administered orally as capsules, tablets, lozenges, a powder or a syrup.



40. (New) The method of claim 27 wherein the glycoposphopeptical is administered topically in the form of eye or nasal preparations such as drops or ointment, or skin or vaginal preparations such as cream and ointment.

41. (New) The method of claim 27 for the treatment of patients suffering from extrinsic asthma, intrinsic asthma or mixed extrinsic/intrinsic asthma.

42. (New) The method of claim 27 for the treatment of patients suffering from allergic and perennial rhinitis, allergic conjunctivitis, chronic urticaria, atopic dermatitis or laryngeal oedema.

43. (New) The method of claim 37 of treating patients suffering from chronic corticosteroid-dependent allergy and asthma.